1292280-40-0

Downstream Products

• 1326301-07-8 [(η⁵-C₅Me₄C₆H₄C₆H₅)Ir(2-phenylpyridine)Cl] 
• 1292280-48-8 [Ir(η⁵-biphenyltetramethylcyclopentadienyl)(bipyridine)Cl]PF₆ 

Relevant academic research and scientific papers

Preparation and Bioactivity of Iridium(III) Phenanthroline Complexes with Halide Ions and Pyridine Leaving Groups

A series of half-sandwich structural iridium(III) phenanthroline (Phen) complexes with halide ions (Cl?, Br?, I?) and pyridine leaving groups ([(η5-CpX)Ir(Phen)Z](PF6)n, Cpx: electron-rich cyclopentadienyl group, Z: leaving group) have been prepared. Target complexes, especially the Cpxbiph (biphenyl-substituted cyclopentadienyl)-based one, showed favourable anticancer activity against human lung cancer (A549) cells; the best one (Ir8) was almost five times that of cisplatin under the same conditions. Compared with complexes involving halide ion leaving groups, the pyridine-based one did not display hydrolysis but effectively caused lysosomal damage, leading to accumulation in the cytosol, inducing an increase in the level of intracellular reactive oxygen species and apoptosis; this indicated an anticancer mechanism of oxidation. Additionally, these complexes could bind to serum albumin through a static quenching mechanism. The data highlight the potential value of half-sandwich iridium(III) phenanthroline complexes as anticancer drugs.

Fluorescent iridium(iii) coumarin-salicylaldehyde Schiff base compounds as lysosome-targeted antitumor agents

Six fluorescent half-sandwich iridium(iii) coumarin-salicylaldehyde Schiff base (O^N) compounds ([(?5-Cp*)Ir(O^N)Cl]) were prepared and characterized. The introduction of a coumarin unit increased the antitumor activity (IC50: 9.9 ± 0.1 μM-40.7 ± 12.9 μM) of these compounds, the best of which was nearly two times that of clinical cisplatin. The results of laser confocal microscopy demonstrated that these compounds possessed an energy-dependent cellular uptake mechanism, accumulated in the lysosomes (Pearson co-localization coefficient: ~0.7), damaged the integrity of the lysosomes, and induced apoptosis. The compounds could also decrease the mitochondrial membrane potential, catalyze the oxidation of the coenzyme (nicotinamide-adenine dinucleotide) and improve the levels of the intracellular reactive oxygen species, following an antitumor mechanism of oxidation. Additionally, these compounds could block the metastasis of tumor cells. Above all, these iridium(iii) compounds show potential as antitumor agents with dual functions: lysosomal damage and anti-metastasis.

Lysosomal-targeted anticancer half-sandwich iridium(III) complexes modified with lonidamine amide derivatives

Ten half-sandwich iridium complexes containing lonidamine amide derivatives were synthesized and characterized. Unlike lonidamine, which acts on mitochondria, its iridium complexes successfully targeted lysosomes and induced lysosomal damage. Antiproliferation studies showed that most of the complexes have higher anticancer activity against A549 and HeLa cells than cisplatin. The antitumor activity of complex 6 is 2.69 times that of cisplatin against A549 cells. We also performed antitumor tests on ligands L1 and L5, and proved that they exhibit excellent antitumor activity only after binding to the metal center. The bovine serum albumin (BSA) binding test showed that the complexes had the ability to bind to BSA, and they interact with BSA by a static mechanism. The complexes can also cause changes in mitochondrial membrane potential and can produce active oxygen species better than active control. NADH/NAD+ transformation experiments were used to determine if the production of ROS was caused by the transformation of NADH/NAD+. We also explored the way that the complexes enter cells.

Half-sandwich iridium(III) complexes with α-picolinic acid frameworks and antitumor applications

Eight half-sandwich iridiumIII (IrIII) complexes of the general formula [(η5-Cpxbiph)Ir(O^N)Cl] (Cpxbiph is tetramethyl(biphenyl)cyclopentadienyl, and the O^N is α-picolinic acid chelating ligand and

With anticancer activity of ion iridium complex and its preparation method, application (by machine translation)

The invention relates to a metal complex, in particular relates to a ion iridium complexes with anticancer activity and its preparation method, application, which belongs to the chemical-pharmaceutical field. The complex structural formula is: , The present invention provides organic iridium complex is a phosphorus-oxygen atom with the iridium coordination complex, has high anticancer activity, small side effect, property is good, and is not easy to produce the drug resistance; the invention provides a preparation method, the synthesis efficiency is high, in the preparation of the complexes in biomedical Sciences has broad application prospects; the invention [P, O] introduced into the neutral ligands of this complex has androgenic activity, for the follow-up anti-cancer pharmaceutical ligand synthetic study provides a new line of research. (by machine translation)

Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents

We, herein, report the synthesis, characterization, luminescence properties, anticancer, and antibacterial activities of a family of novel half-sandwich iridium(III) complexes of the general formula [(n5-Cpx)Ir(C^N)Cl]PF6- [Cpx = pentamethylcyclopentadienyl (Cp) or tetramethyl(biphenyl)-cyclopentadienyl (Cpxbiph)] bearing versatile imine-N-heterocyclic carbene ligands. In this complex framework, substituents on four positions could be modulated, which distinguishes this class of complex and provides a large amount of flexibility and opportunity to tune the cytotoxicity of complexes. The X-ray crystal structures of complexes 4 and 10 exhibit the expected "piano-stool" geometry. With the exception of 1, 2, and 11, each complex shows potent cytotoxicity, with IC50 (half-maximum inhibitory concentration) values ranging from 1.99 to 25.86 μM toward A549 human lung cancer cells. First, the effect of four positions bearing different substituents in the complex framework on the anticancer activity, that is, structure-activity relationship, was systematically studied. Complex 8 (IC50 = 1.99 μM) displays the highest anticancer activities, whose cytotoxicity is more than 10-fold higher than that of the clinical platinum drug cisplatin against A549 cancer cells. Second, their chemical reactivity including nucleobases binding, catalytic activity in converting coenzyme NADH to NAD+, reaction with glutathione (GSH), and bovine serum albumin (BSA) binding is investigated. No reaction with nucleobase is observed. However, these iridium(III) complexes bind rapidly to GSH and can catalyze oxidation of NADH to NAD+. In addition, they show moderate binding affinity to BSA and the fluorescence quenching of BSA by the iridium (III) complexes is due to the static quenching. Third, the mode of cell death was also explored through flow cytometry experiments, including cell cycle, apoptosis induction, reactive oxygen species (ROS) and mitochondrial membrane potential. It seems that cell cycle perturbation, apoptosis induction, increase of ROS level and loss of mitochondrial membrane potential together contribute to the anticancer potency of these complexes. Last, the use of confocal microscopy provides insights into the microscopic mechanism that the typical and most active complex 8 enters A549 lung cancer cells mainly through energy-dependent pathway and is located in lysosome. Furthermore, lysosome damage and nuclear morphology were detected by confocal microscopy. Nuclear condensation and apoptotic bodies may finally induce cells apoptosis. Interestingly, complex 8 also shows antibacterial activity against Gram-positive Staphylococcus aureus. This work may provide an alternative and effective strategy to smart design of potent organometallic half-sandwich iridium(III) anticancer drugs.

Rhodamine B modified semi-sandwich iridium complex with fluorescence characteristics as well as preparation method and application thereof

The invention particularly relates to a rhodamine B modified semi-sandwich iridium complex with fluorescence characteristics as well as a preparation method and application thereof, and belongs to thefield of chemical pharmacy. The complex has a molecular structural formula shown in the description. The rhodamine B is creatively used for modifying the iridium complex; the high anti-cancer activity and the mitochondria targeting performance can be given to the whole complex; the selectivity can be realized on cancer cells; the ideal goals of action process visibility and real-time detection performance can be achieved; the important significance is realized on the medicine targeting performance study. The N^N is used as the two-tooth chelation anion ligand; a novel ion type iridium complexwith higher anti-cancer activity and fluorescence characteristics is synthesized; the complex has the good effect and high activity in anti-cancer and cell imaging aspects.

Carbene imine semi-sandwich iridium complex capable of targeting lysosome as well as preparation method and application thereof

The invention relates to a metal compound, in particular to a carbene imine semi-sandwich iridium complex capable of targeting lysosome as well as a preparation method and application thereof, and belongs to the technical field of chemical pharmacy. The compound has a structure formula shown in the description. The prepared compound can be easily modified, can be modified in a plurality of positions, has good anticancer activity, and belongs to a novel kind of potential anticancer medicine. The condition that the semi-sandwich iridium complex can perform cell imaging through laser a co-focusing microscope is found for the first time; the problem of unclear targeting of the semi-sandwich compound is solved; a method for effectively studying the anticancer mechanism of the compound is provided; the cell imaging result shows that the compound can well target the lysosome.

Half-sandwich iridium N-heterocyclic carbene anticancer complexes

Half-sandwich pseudo-octahedral pentamethylcyclopentadienyl IrIII complexes of the type [(η5-Cpx)Ir(C^C)Cl]PF6, where Cpx is pentamethylcyclopentadienyl (Cp?), or its phenyl (Cpxph = C

Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable: In vitro anticancer activity

Seven novel half-sandwich IrIII cyclopentadienyl complexes, [(η5-Cpx)Ir(N^N)Cl]PF6, have been prepared and characterized, where Cpx is Cp? or the biphenyl derivative Cpxbiph (C5Me4C6H4C6H5), and the N^N-chelating ligands are imino-pyridyl Schiff-bases. The X-ray crystal structures of complexes 2A, 2B, and 3A have been determined. Excitingly, most of the complexes show potent antiproliferative activity towards A549 and HeLa cancer cells, except for Cp? complex 1A towards HeLa cells. Cpxbiph complex 2B displayed the highest potency, about 19 and 6 times more active than the clinically used drug cisplatin toward A549 and HeLa cells, respectively. These complexes undergo hydrolysis, and the kinetics data have been calculated. DNA binding has been studied by interaction with nucleobases 9-ethylguanine and 9-methyladenine, cleavage of plasmid DNA, and interaction with ctDNA. Interaction with DNA does not appear to be the major mechanism of action. Protein binding (bovine serum albumin, BSA) has been established by UV-Vis, fluorescence and synchronous spectroscopic studies. The stability of complex 2B in the presence of GSH was evaluated. The complexes catalytically convert coenzyme NADH to NAD+via hydride transfer. Cpxbiph complexes 2B and 4B induce cell apoptosis and arrest cell cycles at the S and G2/M phases towards A549 cancer cells and increase the reactive oxygen species dramatically, which appear to contribute to the remarkable anticancer activity.